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BRIEF REPORT 
A 56 year-old man presented in fall of 2015 with left flank pain and hematuria. He was 
evaluated by his primary care physician and CT scan showed nephrolithiasis, a left 
renal mass, significant lymphadenopathy in the left hilar region, small indeterminate 
pulmonary nodules, and a small sclerotic lesions in the left femur and left humerus. He 
underwent left radical nephrectomy with excision of retrocrural lymph nodes and 
retroperitoneal lymph node dissection. Pathology revealed a 9cm unclassified renal cell 
carcinoma with 40% sarcomatoid features and invasion into renal vein, perirenal fat, 
and hilar fat (Figure 1A). Tumor was graded as Fuhrman grade 4. Adrenal gland was 
involved by tumor. Three retrocrural and 5 interaortocaval lymph nodes were involved 
with carcinoma. Repeat CT scans post operatively showed enlarging right retrocrural 
lymph node that was not resected during surgery and new lung nodules. Surgical 
pathology was sent for further immunohistochemistry and next-generation sequencing. 
No actionable deoxyribonucleic acid (DNA) mutations, copy number variants, or gene 
fusions were found. Messenger ribonucleic acid (RNA) expression analysis showed 
high expression of the kidney-specific biomarker CA IX (CA9) at 35.3 fold of normal. 
Immunohistochemistry review revealed programmed death-ligand 1 (PD-L1) expression 
on 90% of tumor cells with 3+ intensity (Figure 1B). Moreover, PD-L1 tumor infiltrating 
lymphocytes (TILs) were present in 10% of the tumor sample with 2+ intensity. Given 
the presence of metastatic disease, patient was started on treatment with sunitinib 
50mg orally daily for 4 weeks on and 2 weeks off schedule. Two months after initiating 
treatment of sunitinib, he experienced growing supraclavicular lymph nodes causing 
local pain. Repeat CT scans showed enlarging left supraclavicular (4cm), 
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paraesophageal (2.5cm), right paraspinal (2cm), bilateral retrocrural (2cm), and 
retroperitoneal (2cm) lymphadenopathy. In addition there were growing pulmonary 
nodules, and new liver metastatic disease. Figure 2 shows CT scans of the chest, 
abdomen, and pelvis at the time of progression. Second-line treatment with the 
programmed death-1 (PD-1) inhibitor nivolumab 3mg/kg intravenously every 2 weeks 
was initiated. After 1 dose of nivolumab, patient’s supraclavicular lymphadenopathy was 
no longer palpable and the associated pain subsided. Repeat CT scans after treatment 
with nivolumab showed partial response with marked improvement in lymphadenopathy 
and lung nodules (Figure 3). Some of the previously noted lymph nodes were 
completely resolved and others much smaller in size. In addition there was decrease in 
size of pulmonary and liver metastasis.  
Patient is now 10 months into treatment with nivolumab for his unclassified renal cell 
carcinoma and continues to have a significant response. He has received palliative 
radiotherapy to metastatic disease in the left femoral head and left humerus at a dose of 
20Gy divided over 5 fractions. He has an excellent quality of life and is able to function 
at the level prior to being diagnosed with metastatic unclassified kidney cancer.    
DISCUSSION 
Renal cell carcinoma (RCC) is histologically classified as clear cell RCC, papillary RCC, 
chromophobe RCC, collecting duct RCC, or unclassified RCC.1,2Several reports have 
indicated significant differences in pathologic features and clinical outcomes among 
patients with different RCC histologic subtypes.3,4 Unclassified RCC is comprised of a 
renal cortical epithelial neoplasms that could not be assigned to any of the other RCC 
subtypes based on histologic evaluation and it constitutes 3-5% of cases of RCC.1 
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Unclassified RCC is a category that encompasses a wide range of genetic alterations 
and histologic findings that might contain elements of other histologic subtypes of RCC 
or sarcomatoid features. Tumors with pure sarcomatoid or mixed sarcomatous and 
anaplastic features are also designated as unclassified RCC. These unclassified tumors 
are generally high grade and have unrecognizable cell types. Studies evaluating 
unclassified RCC indicate that these neoplasms are associated with highly aggressive 
biological behavior and poor clinical outcomes.5-12 Patients tend to present with larger 
tumors, have increased risk of invasion to adjacent organs, increased risk for regional 
and non-regional lymph node metastasis, and increased risk for bone metastasis.9 In 
addition, several studies have indicated that patients with unclassified RCC are more 
likely to present with higher grade and stage that are associated with shorter cancer-
specific and overall survival compared to patients with clear-cell RCC.7,8 
In this report, a patient with unclassified RCC developed progressive metastatic disease 
shortly after nephrectomy and retroperitoneal and retrocrural lymph node dissection. 
Next-generation sequencing did not reveal actionable mutations. Further 
immunohistochemistry testing showed 3+ PD-L1 expression on 90% of tumor cells and 
10% of the tumor sample contained TILs with 2+ intensity. Patient rapidly progressed 
after first-line sunitinib with worsening symptoms and progressive disease on imaging. 
Treatment with the PD-1 inhibitor nivolumab was instituted and patient had a clinical 
and anatomic response with resolution of symptoms and regression or resolution of 
metastatic lesions on CT imaging. This response was durable and is currently ongoing 
after 10 months of therapy.  
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To our knowledge, there is limited data of treating patients with unclassified RCC with 
immune checkpoint inhibitor based therapy. Here we report a case of metastatic 
unclassified RCC with high PD-L1 tumor expression and a significant response to 
nivolumab. PD-L1 expression appears to predict response to PD-1/PDL-1 inhibitors in 
lung cancer and melanoma but not in metastatic clear-cell RCC.13-15It is unclear whether 
PD-L1 expression may be a predictive marker of response to immune checkpoint 
inhibitors in non-clear cell RCC, and particularly in the unclassified histotype. The 
findings in this report suggest that further investigation is warranted for utilizing 
checkpoint inhibitors upfront in this subgroup of RCC patients who have limited 
therapeutic options, especially in case of high PD-L1 expression.  
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FIGURE LEGENDS 
- Fig 1:  
Fig 1A: Hematoxylin and eosin (H&E) staining with 10x power of left kidney sample 
showing unclassified renal cell carcinoma with 40% sarcomatoid features. 
Fig 1B: Immunohistochemistry of renal tumor showing programmed death-ligand 1 (PD-
L1) expression on 90% of tumor cells with 3+ intensity at 10x power  
- Fig 2: CT scan at the time of progression on sunitinib showing left supraclavicular 
lymph node measuring 2.9 x 4.1 cm (Fig 2A), paraesophageal lymph node measuring 
2.3 x 2.4 cm (Fig 2B), and right lower lobe lung nodule measuring 1.4 x 1.7 cm (Fig 2C).  
- Fig 3: CT scan after treatment with Nivolumab showing left supraclavicular lymph 
node measuring 1.6 x 1.2 cm (Fig 3A), paraesophageal lymph node measuring 1.3 x 1.0 
cm (Fig 3B), and right lower lobe lung nodule measuring 0.5 x 0.5 cm (Fig 3C).   
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